List view / Grid view
27 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU...
21 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
19 November 2014 | By Boehringer Ingelheim
Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin...
19 November 2014 | By Boehringer Ingelheim
New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism...
28 October 2014 | By Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
21 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer...
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
29 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of nintedanib*...
16 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes...
15 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the multinational RE-VERSE AD clinical trial – the study investigating the emergency reversal of the anticoagulant effect of dabigatran – has been initiated in the UK...
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
8 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU...
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
1 September 2014 | By Boehringer Ingelheim
The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio...
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
